The management of brain tumor-related epilepsy does not differ substantially from that used in epilepsies of other etiologies.
The choice of an antiepileptic drug is based on tolerability and pharmacokinetic interactions with chemotherapeutic
drugs. Levetiracetam is recommended as first-line therapy in brain tumor-related epilepsy. Due to the interactions,
enzyme-inducing antiepileptic drugs are not recommended as a first choice and the combination with chemotherapeutic
drugs is not recommended also. There is no evidence for use of prophylactic prescription of long-term antiepileptic
drug treatment in patients with brain tumors who did not present with seizures. Because of the high risk of recurrence,
the treatment should started immediatelly after a first brain tumor-related seizure.The decision to withdraw antiepileptic
drugs must consider the prognosis of tumor and risk of seizure recurrence.